放疗进展及其对第二原发癌风险的影响:一项前列腺癌患者多中心队列研究
该多中心队列研究纳入五个荷兰放疗机构2000-2016年间7908例接受外照射放疗的局限期前列腺癌患者,分析放疗方案特征与第二原发癌风险的关系。结果显示先进放疗技术与盆腔及非盆腔第二原发癌风险升高均无显著关联,其他放疗方案特征亦与第二原发癌终点不相关。作者认为随着放疗方案不断演进,持续评估相关第二原发癌风险仍很重要。
要点
- 其他放疗方案特征与第二原发癌终点均不相关。
核心结论
- 所研究的先进外照射放疗方案特征均与野外的第二原发癌风险升高无关联。
- 随着外照射放疗方案持续演进,评估相关第二原发癌风险仍然重要。
研究设计与样本
- 多中心队列研究,收集五个荷兰放疗机构2000-2016年间7908例局限期前列腺癌患者的外照射放疗方案特征。
- 从荷兰癌症登记处获取患者与肿瘤特征、第二原发癌数据及生存信息。
- 计算盆腔与非盆腔第二原发癌的标准化发病比(SIR),并以全国SIR作为参考,以日历时期作为区分3D-CRT与先进外照射放疗的替代指标。
主要发现
- 2000-2006年间,最主导的方案为3D-CRT,总剂量68-78 Gy,每次2 Gy,使用10-23 MV射线,并每周进行门静脉成像。
- 到2010年,所有机构均常规使用先进外照射放疗(IMRT、VMAT、螺旋断层放疗),主要给予78 Gy,每次2 Gy,采用多种kV/MV成像方案。
- 1268例(16%)发生至少1种第二原发癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Modelling studies suggest that advanced intensity-modulated radiotherapy may increase second primary cancer (SPC) risks, due to increased radiation exposure of tissues located outside the treatment fields. In the current study we investigated the association between SPC risks and characteristics of applied external beam radiotherapy (EBRT) protocols for localized prostate cancer (PCa). METHODS: We collected EBRT protocol characteristics (2000-2016) from five Dutch RT institutes for the 3D-CRT and advanced EBRT era (N = 7908). From the Netherlands Cancer Registry we obtained patient/tumour characteristics, SPC data, and survival information. Standardized incidence ratios (SIR) were calculated for pelvis and non-pelvis SPC. Nationwide SIRs were calculated as a reference, using calendar period as a proxy to label 3D-CRT/advanced EBRT. RESULTS: From 2000-2006, 3D-CRT with 68-78 Gy in 2 Gy fractions, delivered with 10-23 MV and weekly portal imaging was the most dominant protocol. By the year 2010 all institutes routinely used advanced EBRT (IMRT, VMAT, tomotherapy), mainly delivering 78 Gy in 2 Gy fractions, using various kV/MV imaging protocols. Sixteen percent (N = 1268) developed ≥ 1 SPC. SIRs for pelvis and non-pelvis SPC (all institutes, advanced EBRT vs 3D-CRT) were 1.17 (1.00-1.36) vs 1.39 (1.21-1.59), and 1.01 (0.89-1.07) vs 1.03 (0.94-1.13), respectively. Nationwide non-pelvis SIR was 1.07 (1.01-1.13) vs 1.02 (0.98-1.07). Other RT protocol characteristics did not correlate with SPC endpoints. CONCLUSION: None of the studied RT characteristics of advanced EBRT was associated with increased out-of-field SPC risks. With constantly evolving EBRT protocols, evaluation of associated SPC risks remains important.
引用
- Jahreiß MC, Hoogeman M, Aben KK, et al. Advances in radiotherapy and its impact on second primary cancer risk: A multi-center cohort study in prostate cancer patients. Radiother Oncol. 2023. PMID: 37003369. doi:10.1016/j.radonc.2023.109659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。